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Long non-coding RNAs (lncRNAs) are a class of RNA with transcripts longer than 200 
nucleotides that lack functional open reading frames. They play various roles in human 
carcinoma, such as dysregulating gene expression in prostate cancer (PCa), which results 
in cancer initiation, development, and progression. The non-coding RNA SChLAP1 
(second chromosome locus associated with prostate-1) is highly expressed in approxi-
mately 25% of PCas with higher prevalence in metastatic compared to localized PCa. Its 
expression is detectable non-invasively in PCa patient urine samples. Experimental data 
suggest that targeting SChLAP1 may represent a novel therapeutic application in PCa. 
This contribution focuses on the role of lncRNAs SChLAP1 expression in PCa diagnosis 
and prognosis.
Keywords: second chromosome locus associated with prostate-1, metastatic prostate cancer, long non-coding 
RnA, lethal prostate cancer, prognostic biomarker, marker of aggressiveness
inTRODUCTiOn
Prostate cancer (PCa) is the most commonly diagnosed cancer and the second major cause of cancer 
death in man (1). It is characterized by a wide and heterogeneous spectrum of clinical behaviors, 
ranging from indolent to aggressive forms. The clinical and morphological methods and features 
currently used in the routine show a low-predictive value concerning the definition of its level 
of aggressiveness (2, 3). Predictive and prognostic markers can be determined with clinical and 
pathological parameters, such as serum prostate-specific antigen (PSA), Gleason score (GS), and 
TNM stage. Due to PCa heterogeneity, patients with similar TNM stage, GS, and PSA could show 
opposite outcomes (4).
Additional predictive and prognostic markers are needed to distinguish high-risk from low-risk 
PCa patients. To this end, genetic and epigenetic investigations have been made to understand the 
complex genomic landscape of PCa in order to improve its diagnosis and prognosis and to define the 
potential role of new therapeutical targets (5). Long non-coding RNAs (lncRNAs), a class of RNA 
with transcripts longer than 200 nucleotides without functional open reading frames, play various 
roles in human carcinoma (6, 7).
2Cimadamore et al. SChLAP1 Expression in Prostate Cancer
Frontiers in Oncology | www.frontiersin.org December 2017 | Volume 7 | Article 305
This contribution focuses on the role of lncRNAs second chro-
mosome locus associated with prostate-1 (SChLAP1) expression 
in PCa diagnosis and prognosis.
LOnG nOn-CODinG RnAs
Long non-coding RNAs are a class of RNA with transcripts longer 
than 200 nucleotides that lack functional open reading frames 
(6). Based on their locations in the genome relative to protein-
coding genes, lncRNAs have been subdivided into intergenic 
and intragenic. Intragenic lncRNAs can be further subclassified 
as exonic, intronic, and overlapping lncRNAs (8). Since protein-
coding genes have been the focus of most research, the functional 
role of lncRNAs has been either underestimated or neglected (9).
As shown by Rinn and Chang, “More than 90% of human 
genome transcripts, including lncRNAs, do not code for proteins” 
(10). However, accumulating evidence suggests that lncRNAs 
play a role in the development of various types of cancers, such 
as PCa, hepatocellular carcinoma, non-small cell lung cancer, 
leukemia, colon carcinoma, and breast cancer (11–16).
While the mechanism of many lncRNAs remains to be 
elucidated, it has become clear that lncRNAs contribute to 
dysregulation of gene expression in PCa, thus resulting in cancer 
initiation, development, and progression (17).
lncRnAs in PROSTATe CAnCeR
Elucidating the roles of lncRNAs in PCa holds great promise 
for early detection, prevention, and treatment. A well-known 
example is prostate cancer antigen3 (PCA3), also known as DD3, 
initially discovered via expression profiling of prostate sample 
(18). PCA3 has been extensively studied as a PCa-specific bio-
marker in body fluids. PCA3 urine RNA assay predicts biopsy 
status and histopathological characteristics (19). However, it does 
not predict outcomes such as recurrence and metastasis.
Another lncRNA investigated in PCa is metastasis-associated 
lung adenocarcinoma transcript-1 (MALAT-1), originally 
known to be overexpressed in patients at high risk for non-
small cell lung cancer metastasis, as its name implies (20, 21). Its 
expression is found in many other human solid tumors having 
close correlation with invasiveness and metastasis (22–26). Ren 
and colleagues found that MALAT-1 is overexpressed in PCa 
compared to adjacent normal tissue (20). MALAT-1 expression 
is significantly higher in castration-resistant PCa (CRPCa) 
than in primary prostate tumor. Its expression increases from 
hormone sensitive to CRPCa. The same group of authors 
showed that this lncRNA could be a promising  therapeutic 
target in patients with CRPCa. The intratumoral administration 
of therapeutic MALAT-1 siRNA suppressed CRPCa growth 
and  metastasis in  vivo, and prolonged the  survival of tumor 
bearing mice (20).
It has also been shown that urine MALAT-1 is an independent 
predictor of PCa, more accurate than routine PSA. Its use would 
prevent one-third of unnecessary biopsies in PSA 4–10  ng/ml 
cohorts, without missing any high-grade PCa (27). Furthermore, 
in 192 plasma samples, MALAT-1 achieved high diagnostic 
accuracy in predicting prostate biopsy outcomes and, therefore, 
it might also be utilized as a plasma-based biomarker for PCa 
detection (28).
Recently, Zhao et  al. investigated the expression profile 
of FALEC, another lncRNA, in PCa. Like other lncRNAs, its 
expression is significantly higher in PCa than adjacent normal 
parenchyma. Its downregulation inhibits cell proliferation, 
migration, and invasion (29).
Similar results were obtained with CCAT2, a lncRNA 
involved in proliferation, migration, and invasion of PCa cells. 
In particular, it was demonstrated that silencing of CCAT2 was 
able to inhibit N-cadherin, vimentin expression, and improve the 
expression level of E-cadherin, thus leading to the stimulation 
of epithelial-mesenchymal transition. High expression level of 
CCAT2 correlates with poor overall survival and progression-
free survival and could be considered an independent prognostic 
factor in patients with PCa (30). Another promising lncRNA is 
LOC400891 which showed high expression in patients with an 
advanced PCa and a shorter biochemical recurrence-free survival 
time (31).
An interesting feature of lncRNAs is that many of them are 
not PCa specific. For example, we can observe overexpression of 
lncRNA-ATB in gastric cancer (32), hepatocellular carcinoma 
(33), osteosarcoma (34), and other tumors. Its tissue overexpres-
sion is directly proportional with the histological grade, high 
preoperative PSA level, pathological stage, high GS, lymph node 
metastasis, angiolymphatic invasion, and biochemical recurrence 
in PCa patients (35).
lncRnA-Based Signature
Signatures, based on microarray lncRNA expression profiling, 
have been recently developed and widely used in prediction of 
a series of tumor characteristics and outcomes in various cancer 
type (36, 37). However, due to its low expression characteristics, 
a single lncRNA analysis might be associated with false-positive 
result. To overcome this problem, Huang and colleagues have 
developed a risk score based on lncRNA expression profile (38). 
They found four lncRNAs are significantly associated with BCR-
free survival. Among the four lncRNAs, two (RP11-108P20.4 and 
RP11- 757G1.6) were positively associated with BCR-free survival, 
while the remaining two (RP11-347I19.8 and LINC01123) were 
negatively associated with BCR-free survival. They estimated a 
risk score for each patient and then divided patients into a high-
risk group and a low-risk group by using the median risk score as 
the cutoff point. The four-lncRNA signature has been shown to 
be a powerful prognostic factor, independent of age, tumor and 
lymph node status, GS, margin status, and adjuvant postoperative 
radiotherapy (38) in (Table 1).
SeCOnD CHROMOSOMe LOCUS 
ASSOCiATeD wiTH PROSTATe-1
About 1,800 lncRNAs were identified by Presner et al. through 
the application of RNA sequencing techniques (i.e., transcrip-
tome sequencing) on a consistent number of tissue samples. Of 
these 1,800 lncRNAs, 121 resulted transcriptionally dysregulated 
in PCa (39). Such 121 Prostate Cancer-Associated Transcripts 
TABLe 1 | Other lncRNAs associated with prostate cancer.
PCA3 Urine marker useful to predict biopsy status and 
histopathological characteristics (19)
MALAT-1 Its expression increases from hormone sensitive to  
CRPCa (20). Useful plasma biomarker for PCa  
detection (28)
FALEC Its inhibition decreases cell proliferation, migration, and 
invasion (29)
CCAT2 Its high expression levels correlates with poor overall survival 
and progression-free survival (30)
LOC400891 Its high expression correlates with shorter BCR-free survival 
time (31)
ATB Its high expression correlates with preoperative PSA 
levels, pathological stage, GS, lymph node metastasis, 
angiolymphatic invasion, and BCR (35)
RP11-108P20.4 Positively associated with BCR-free survival
RP11-757G1.6 Part of the Four-lncRNA signature (38)
RP11-347I19.8 Negatively associated with BCR-free survival
LINC01123 Part of the Four-lncRNA signature (38)
CRPCa, castration resistant; PCa, prostate cancer; BCR, biochemical recurrence; PSA, 
prostate-specific antigen; GS, Gleason score; lncRNAs, long non-coding RNAs.
FiGURe 1 | Working model of second chromosome locus associated with 
prostate-1 (SChLAP1) in prostate cancer (PCa). There are two pathways. In 
Pathway 1, loss of SWI/SNF functionality promotes cancer progression (41). 
In Pathway 2, miR-198 might exert its anticancer effect through inhibition of 
MAPKs signaling pathway. SChLAP1 acts as a negative regulator in the 
expression of miR-198 and subsequently modulates the MAPK1 signaling 
pathway in PCa (49).
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represent an unbiased list of potentially functional lncRNAs asso-
ciated with PCa. By performing a cancer outlier profile analysis 
to identify intergenic lncRNAs selectively upregulated in a subset 
of cancers, they found two lncRNAs, PCAT-109 and PCAT-
114, both located on Chromosome 2q31.3 in a “gene desert,” a 
region of the genome that are lacking of protein-coding genes. 
Both genes showed “outlier profiles and ranked among the best 
outliers in PCa” (40). In particular, PCAT-114 was found to be 
overexpressed in prostate cell lines. It was named SChLAP1 after 
its genomic location (40). Schlap1 gene has a transcript length of 
24,484 Kb. The complete gene is composed of 7 exons and 1,675 
nucleotides. The primary transcript (isoform 1) is composed of 5 
exons with a length of 1,436 nucleotides. As a result of a spicing 
process, a total of 8 isoforms were found, with isoform 1, isoform 
2, and 3 accounting for >90% of transcripts (41). RNA-seq, per-
formed on 27 different tissue samples from 95 human individuals, 
showed that SChLAP1 expression was highly specific for prostate 
tissue, being present at minor levels in bladder, kidney, and testis 
samples (42).
SChLAP1’s working Mechanisms: 
interaction with Swi/SnF Complex and 
miR-198
In vitro and in vivo gain-of-function and loss-of-function experi-
ments have shown that SChLAP1 plays a crucial role in cancer 
cell invasiveness and metastasis, antagonizing the activity of the 
SWI/SNF chromatin-modifying complex, a multiprotein system 
able to move nucleosomes at gene promoters. In particular, such 
experiments showed that the inactivation of SWI/SNF complex 
promoted cancer progression and that multiple SWI/SNF com-
ponents were somatically inactivated in cancer (41, 43). As shown 
by Prensner, even though “other lncRNAs, such as HOTAIR and 
HOTTIP, are known to assist epigenetic complexes such as PRC2 
and MLL by facilitating their genomic binding and enhancing 
their functions, SChLAP1 is the first lncRNA that impairs a major 
epigenetic complex with well-documented tumor suppressor 
function” (41, 44).
In vivo, SChLAP1 has been shown to be implicated in tumor 
cell proliferation and metastasization, as evidenced by both the 
reduction of tumor growth kinetics and the decreased number 
and dimensions of metastatic sites as a consequence of the intra-
cardiac injection of 22Rv1 cells with SChLAP1 knockdown in 
CB-17 SCID mice (41).
Recent studies have shown interaction between SChLAP1 
and miR-198. MiR-198 is downregulated in many cancers, such 
as gastric cancer, lung cancer, and hepatocellular carcinoma 
(45–47). miR-198 suppress the proliferation and invasion of 
colorectal carcinoma (48). miR-198 might exert its anticancer 
effect through inhibition of MAPKs signaling pathway (49). In 
PCa tissue, a low expression of miR-198 was found. As shown 
by Li et al., “knockdown of SChLAP1 significantly increased the 
expression of miR-198 and SChLAP1 overexpression markedly 
decreased it. Thus, SChLAP1 acted as a negative regulator in the 
expression of miR-198” and subsequently modulated the MAPK1 
signaling pathway in PCa (49) (Figure 1). Transfecting PCa cells 
with a designed-specific siRNA to knockdown SChLAP1 expres-
sion, investigators have obtained, as expected, a significantly 
reduction in cell proliferation together with an increase in 
apoptosis-associated proteins. Furthermore, SChLAP1 knock-
down determined a decrease of MMP-9, MMP-14, and VEGF 
expressions both in vitro and in vivo, confirming its involvement 
in cancer invasiveness and metastasis (49). All such findings show 
multiple interactions between SChLAP1 and factors involved in 
oncogenesis and cancer progression and explain the mechanism 
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through which SChLAP1 promotes migration and invasion of 
PCa (50). Understanding this molecular pathway is essential for 
exploring new potential strategies for early diagnosis and therapy.
SChLAP1: Predictor of Aggressive PCa
Second chromosome locus associated with prostate-1 is highly 
expressed in approximately 25% of PCa, expression being higher 
in metastatic compared to localized prostate cancers. It was asso-
ciated with ETS gene fusions (41). Multivariate and univariate 
regression analyses have demonstrated that SChLAP1 expression 
is an independent predictor of PCa aggressiveness with highly 
significant hazard ratios for predicting BCR, clinical progression 
to systemic disease, and PCa-specific mortality, compared to 
other clinical factors such as advanced clinical stage and the GS 
(41). Moreover, SChLAP1 expression was significantly associated 
with extracapsular extension, seminal vesicle invasion, and posi-
tive surgical margin status (40).
Validation in three-independent cohorts has confirmed the 
prognostic value of SChLAP1 for metastasis. On multivariate 
modeling, SChLAP1 expression independently predicted metas-
tasis within 10  years, death within 10  years, and biochemical 
recurrence within 5  years with odds ratios, comparable to GS. 
Among all known genes, the lncRNA SChLAP1 ranked first for 
elevated expression in patients with metastatic progression by 
receiver-operator-curve area-under-the-curve analyses and was 
the only prostate-specific gene, ideal for development as a non-
invasive biomarker (40).
Similar results have been obtained by Mehra and colleagues 
using a novel RNA in  situ hybridization (ISH) assay for detec-
tion of SChLAP1 in formalin-fixed, paraffin-embedded tissue 
(51). They found that high SChLAP1 expression independently 
predicts biochemical PCa recurrence after radical prostatectomy 
in patients with clinically localized PCa and that it is associated 
with the development of lethal PCa.
Interestingly, high SChLAP1 expression is associated with 
lethal PCa among patients with non-advanced clinical tumor 
stage. Similarly, high SChLAP1 expression is associated with 
lethal PCa among patients with low grade tumors (GS ≤7). 
However, using SChLAP1 as prognostic test, investigators have 
obtained a sensitivity around 24% and a specificity of 94% in the 
group of non-advanced clinical tumor stage and in the group with 
a 6–7 GS (52). Considering the low sensitivity of the test in the 
identification of an aggressive disease in contrast with low-risk 
morphological features, the evaluation of SChLAP1expression 
alone does not seem to improve treatment decision. In conjunc-
tion with other prognostic tools, SChLAP1 has been shown to 
improve upon established clinical algorithms for the risk stratifi-
cation of PCa patients, specifically the CAPRA-S score (53, 54), 
i.e., one of the best clinic-pathological models to date. SChLAP1 
further improves prediction upon both the Decipher test 50 and 
the CCP gene signature (55, 56).
Recently, Chua et al. have investigated SChLAP1 expression 
in subsets of PCa characterized by cribriform architecture (CA) 
and intraductal carcinoma (IDC), features both associated with 
increased risks of biochemical relapse and metastasis. Besides the 
histological presentation, IDC/CA+ cancers harbor an increased 
percentage of genome aberration (PGA). This is in agreement 
with the observation that tumors with IDC or genomic instabil-
ity have a greater metastatic potential. Using mRNA abundance 
analyses and assessing >25,000 genes, they found that SChLAP1 
was surprisingly the only gene with more than threefold higher 
expression in IDC/CA+ compared to IDC/CA− cancers (57).
The association of SChLAP1 expression within IDC/CA+ 
tumors has also been further demonstrated by SChLAP1 RNA-
ISH in prostatectomy TMA-cores. The SChLAP1+, IDC/CA+ 
subgroup has shown a significant increase of biochemical relapse, 
independent of PGA. Combining histology features of cribriform 
architecture and intraductal carcinoma with genomic instability 
or SChLAP1 expression can stratify patients for recurrence more 
accurately than any parameter alone. Interestingly, SChLAP1 
RNA-ISH diffuse expression has been observed in the cribriform 
architecture and intraductal carcinoma and in the adjacent inva-
sive adenocarcinoma. This further supports a field defect and a 
common clonal ancestor to both histopathologies (58).
SChLAP1 in Urine Sediments
Second chromosome locus associated with prostate-1 expression 
is detectable non-invasively in PCa patient in urine samples. Its 
expression is both more frequent and more highly elevated in GS 
7 compared to GS 6 patients even if it is less sensitive than PCA3 
and TMPRSS-ERG gene fusion (40). “SChLAP1 expression may 
complement existing urine diagnostic assays, including PCA3 
and TMPRSS2-ERG, and that clinical application of a SChLAP1 
urine test would be most effective in conjunction with these, and 
potentially other, urine assays” (59).
SChLAP1 As a Potential Drug Target
RNA interference (RNAi) technology using short interfering 
RNA (si-RNA) has shown great potential in the treatment of 
cancers through silencing of specific genes. In vitro and in vivo 
experiments have demonstrated that SChLAP1-knockdown 
promoted apoptosis and inhibited cell proliferation and inva-
sion (41, 49). SChLAP1 is also overexpressed in bladder cancer 
compared to paired normal bladder tissues. Cell transfected with 
SChLAP1 siRNA showed growth arrest, apoptosis, and migration 
inhibition, suggesting oncogenic roles in bladder cancer and a 
potential therapeutic target (Table  2) (60). Such results might 
be the starting point to investigate the therapeutical potential of 
antagonizing SChLAP1 oncogenic functions (60).
lncRnA in DiAGnOSiS, PROGnOSiS, AnD 
TReATMenT: PROS AnD COnS
There are Pros and Cons with the use of lncRNA in the diagnosis 
and treatment of PCa patients. Indeed, lncRNA may represent a 
useful biomarker that can give to clinicians fundamental infor-
mation on tumor biological behavior and aggressiveness, leading 
to the possibility of designing personalized and tailored strategies 
for a single PCa patient. This may also allow an optimization of 
patients’ outcome and to avoid useful costs and consequences of 
not effective therapies for PCa patients.
As far as the Cons, tumor aggressiveness is the result of a 
complex process that involves lncRNA and a variety of driver 
TABLe 2 | SChLAP1 expression in prostate cancer.
Reference Result Method no. specimens
Prensner (39) • 121 novel lncRNA loci (out of >1,800) were aberrantly expressed in PCa  
tissues
• Only two, PCAT-109 and PCAT-114, showed striking outlier profiles and  
ranked among the best outliers in PCa
RNA-Seq; COPA 102 PCa tissue samples and 
cell lines
Prensner (41) • SChLAP1 expression is an independent predictor of PCa aggressiveness with 
highly significant hazard ratios for predicting BCR, CP, and PCSM
• SChLAP1 antagonizes tumor-suppressive functions of the SWI/SNF complex
qPCR 235 RP localized PCa
Prensner (40) • SChLAP1 expression independently predicted metastasis, PCa-specific death, 
and BCR with OR comparable to GS
• SChLAP1 expression was detectable non-invasively in urine samples and 
associated with higher-risk patients
RNA extraction, microarray 
hybridization; qPCR
1,008 patients. Three 
independent cohorts; 230 
urine sediment samples
Mehra (51) • SChLAP1 expression is enriched in samples from tumors with high GSs (≥8) 
compared to tumors with lower GSs
• High SChLAP1 expression independently predicts BCR (PSA relapse) after RP
ISH 160 clinically localized PCa
Mehra (52) • High SChLAP1 expression is significantly associated with a higher risk of 
lethal PCa and PCa-specific death independent of age at diagnosis, GS, and 
pathologic stage
• High SChLAP1 expression is associated with lethal PCa among patients with 
non-advanced clinical tumor stage, but not among patients with advanced 
clinical tumor stage
ISH 937 PCa patients
Zhang (60) • SChLAP1 was overexpressed in bladder cancer tissues compared to paired 
normal bladder tissues
• Cell growth arrest, apoptosis induction, and migration inhibition were also 
observed in bladder cancer cells after transfection with SChLAP1 siRNA
qPCR; CCK-8 assay, flow 
cytometry analysis, and 
wound healing assay
Bladder cancer T24 and 5,637 
cells
Chua (57) • SChLAP1 was the only gene expressed at >3-fold higher in intraductal 
carcinoma (IDC) and cribriform architecture (CA) PCa than in IDC/CA - tumors
Profiling of mRNA abundance, 
ISH
1,325 localized PCa
Li (49) • Knockdown of SChLAP1 promoted apoptosis and inhibited cell proliferation  
and invasion in vitro and in vivo
• SChLAP1 acted as a negative regulator in the expression of miR-198 and 
accelerates the proliferation and metastasis of PCa promoting the MAPK1 
pathway
Not available Not available
RNA-Seq, next generation transcriptome sequencing; COPA, cancer outlier profile analysis; PCa, prostate cancer; qPCR, quantitative Polymerase Chain Reaction; FFPE, 
formalin-fixed paraffin embedded; BCR, biochemical recurrence; CP, clinical progression; PCSM, prostate cancer-specific mortality; GS, Gleason score; OR, odds ratio; RP, radical 
prostatectomy; ISH, in situ hybridization; SChLAP1, second chromosome locus associated with prostate-1; lncRNAs, long non-coding RNAs.
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genes, leading to the necessity for uropathologists to test and 
validate not a single driver gene, but a panel of genes with direct 
consequences on the relative costs of these procedures.
COnCLUSiOn
In conclusion, research on lncRNAs in PCa is at its onset. 
However, as shown in this review:
• The first set of data has revealed central roles with clin-
ical significance for lncRNAs in different stages of the 
disease.
• There is evidence that lncRNAs, including SChLAP1, are 
critical in PCa development and progression.
• Concerning future perspective, mainly based on experimental 
data, targeting SChLAP1 may become a novel therapeutic 
application in PCa.
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